Time to Sell Illumina, Inc. After Today’s Option Traders Bearish Bets?

 Time to Sell Illumina, Inc. After Today's Option Traders Bearish Bets?

In today’s session Illumina, Inc. (ILMN) recorded an unusually high (157) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious ILMN decrease. With 157 contracts traded and 10774 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: ILMN161216P00130000 closed last at: $4.2 or 7.7% up. About 825,631 shares traded hands. Illumina, Inc. (NASDAQ:ILMN) has declined 13.52% since March 30, 2016 and is downtrending. It has underperformed by 16.54% the S&P500.

Illumina, Inc. (NASDAQ:ILMN) Ratings Coverage

Out of 22 analysts covering Illumina Inc (NASDAQ:ILMN), 7 rate it a “Buy”, 1 “Sell”, while 14 “Hold”. This means 32% are positive. Illumina Inc has been the topic of 45 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Focus List” rating by Citigroup given on Wednesday, August 26. The rating was maintained by Morgan Stanley with “Equal-Weight” on Tuesday, May 3. The stock has “Outperform” rating given by Cowen & Co on Tuesday, April 19. Leerink Swann downgraded Illumina, Inc. (NASDAQ:ILMN) rating on Thursday, October 1. Leerink Swann has “Market Perform” rating and $185 price target. The stock of Illumina, Inc. (NASDAQ:ILMN) earned “Neutral” rating by Goldman Sachs on Tuesday, October 6. Argus Research initiated the shares of ILMN in a report on Wednesday, March 30 with “Buy” rating. The stock of Illumina, Inc. (NASDAQ:ILMN) earned “Hold” rating by Cantor Fitzgerald on Tuesday, April 19. The stock of Illumina, Inc. (NASDAQ:ILMN) earned “Equal-Weight” rating by Barclays Capital on Tuesday, October 13. Piper Jaffray maintained Illumina, Inc. (NASDAQ:ILMN) rating on Wednesday, October 21. Piper Jaffray has “Overweight” rating and $219 price target. The company was downgraded on Thursday, January 7 by Wells Fargo.

According to Zacks Investment Research, “Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company’s tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.”

Insitutional Activity: The institutional sentiment decreased to 1.1 in Q2 2016. Its down 0.03, from 1.13 in 2016Q1. The ratio is negative, as 66 funds sold all Illumina, Inc. shares owned while 150 reduced positions. 46 funds bought stakes while 191 increased positions. They now own 137.98 million shares or 3.82% less from 143.46 million shares in 2016Q1.
Telemus Cap Ltd Liability Corporation owns 2,093 shares or 0.04% of their US portfolio. Comerica Bank & Trust has 42,225 shares for 0.06% of their US portfolio. State Of Wisconsin Board has 0.11% invested in the company for 193,313 shares. Farmers Merchants holds 35 shares or 0% of its portfolio. Fiera holds 105,731 shares or 0.08% of its portfolio. The United Kingdom-based Aberdeen Asset Mngmt Public Ltd Com Uk has invested 0.01% in Illumina, Inc. (NASDAQ:ILMN). Cambridge Advisors holds 0.01% of its portfolio in Illumina, Inc. (NASDAQ:ILMN) for 2,851 shares. Bokf Na last reported 6,274 shares in the company. Hartford Financial Mgmt Inc holds 0.02% of its portfolio in Illumina, Inc. (NASDAQ:ILMN) for 275 shares. Calamos Advsrs Ltd has 0.06% invested in the company for 65,212 shares. Reynders Mcveigh Cap Limited Liability Corporation has invested 1.8% of its portfolio in Illumina, Inc. (NASDAQ:ILMN). Moreover, Jpmorgan Chase Com has 0.22% invested in Illumina, Inc. (NASDAQ:ILMN) for 6.36M shares. Sands Limited Liability Company holds 6.65 million shares or 2.89% of its portfolio. Credit Suisse Ag has 446,130 shares for 0.07% of their US portfolio. Guggenheim Ltd Liability has invested 0.18% of its portfolio in Illumina, Inc. (NASDAQ:ILMN).

Insider Transactions: Since May 12, 2016, the stock had 0 buys, and 27 insider sales for $17.12 million net activity. Shares for $51,081 were sold by EPSTEIN ROBERT S. FLATLEY JAY T also sold $3.46 million worth of Illumina, Inc. (NASDAQ:ILMN) shares. Another trade for 4,000 shares valued at $668,880 was made by WHITFIELD ROY A on Friday, August 12. Shares for $21,156 were sold by Dadswell Charles. HENRY CHRISTIAN O had sold 2,141 shares worth $309,867 on Wednesday, May 25. BOWMAN A BLAINE sold 5,000 shares worth $675,388. 600 shares were sold by BRADBURY DANIEL, worth $110,613.

Illumina, Inc. offers sequencing and array solutions for genetic analysis. The company has a market cap of $19.93 billion. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. It has a 47.58 P/E ratio. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

ILMN Company Profile

Illumina, Inc. (Illumina), incorporated on May 16, 2000, offers sequencing and array solutions for genetic analysis. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina provides sample-to-answer solutions to its clients in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. Illumina provides reproductive-health solutions, including preimplantation genetic screening and diagnosis (PGS and PGD), noninvasive prenatal testing (NIPT), and neonatal and genetic health testing. The Company’s BaseSpace platform, which can be hosted onsite or in the cloud, integrates directly with its sequencing instruments, facilitates data sharing, provides data-storage solutions and streamlines analysis. It has activities in the United States, Europe, Asia-Pacific and other markets.

More important recent Illumina, Inc. (NASDAQ:ILMN) news were published by: Fool.com which released: “Illumina, Inc. in 3 Charts” on October 26, 2016, also Fool.com published article titled: “Why Illumina, Inc. Is Plunging Today”, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 21, 2016. More interesting news about Illumina, Inc. (NASDAQ:ILMN) was released by: Investorplace.com and their article: “3 Stocks to Watch Tuesday: Illumina, Inc. (ILMN), Seagate Technology PLC (STX …” with publication date: October 11, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment